We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Spectral Announces Status of Second Interim Analysis
News

Spectral Announces Status of Second Interim Analysis

Spectral Announces Status of Second Interim Analysis
News

Spectral Announces Status of Second Interim Analysis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Spectral Announces Status of Second Interim Analysis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Spectral Diagnostics Inc. has announced that the Data Safety Monitoring Board (DSMB) has evaluated the safety, efficacy and futility of its EUPHRATES trial based on actual data for 184 randomized patients followed for 28 days.

The DSMB has recommended that the trial continue, but has asked that further analysis be performed before recalculation of the trial's sample size is finalized.

"The Company will await the specifics of the DSMB report, expected soon, before determining next steps in its clinical and commercial pathway," said Dr. Paul Walker, President and CEO of Spectral Diagnostics.

Advertisement